- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026 | 2 | GlobeNewswire (USA) | ||
| Di | Greenwich LifeSciences abstracts accepted at AACR 2026 meeting | 2 | Investing.com | ||
| GREENWICH LIFESCIENCES Aktie jetzt für 0€ handeln | |||||
| 27.01. | Greenwich LifeSciences reports $12.5 million cash balance | 2 | Investing.com | ||
| 27.01. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy | 160 | GlobeNewswire (Europe) | STAFFORD, Texas, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,... ► Artikel lesen | |
| 26.01. | Greenwich LifeSciences-Aktie: Wird sie zum Impfstoff-Überflieger? | 299 | sharedeals.de | Die Aktie von Greenwich LifeSciences sorgte kürzlich mit einem Unternehmensupdate für neue Aufmerksamkeit. Ausschlaggebend ist weniger ein klinischer Meilenstein als vielmehr ein regulatorischer Fortschritt... ► Artikel lesen | |
| 22.01. | GLSI Stock Surges After FDA Clears Use Of Commercial GP2 In Phase III Trial | 1 | RTTNews | ||
| 22.01. | Greenwich LifeSciences: Kurssprung nach FDA-Zulassung für kommerzielle Charge in Phase-III-Studie | 16 | Investing.com Deutsch | ||
| 22.01. | Greenwich LifeSciences surges as FDA clears commercially manufactured product candidate | 1 | Seeking Alpha | ||
| 22.01. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01 | 857 | GlobeNewswire (Europe) | STAFFORD, Texas, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,... ► Artikel lesen | |
| 29.12.25 | Greenwich LifeSciences: Aktie legt nach verlängerter Insider-Sperrfrist kräftig zu | 5 | Investing.com Deutsch | ||
| 29.12.25 | Greenwich LifeSciences verlängert Haltefrist für Insider-Aktien bis September 2026 | 3 | Investing.com Deutsch | ||
| 29.12.25 | Greenwich LifeSciences extends insider share lock-up to Sept 2026 | 1 | Investing.com | ||
| 29.12.25 | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Extends Lock-up of Directors and Officers to September 30, 2026 | 1 | GlobeNewswire (USA) | ||
| 26.12.25 | What's Going On With Greenwich LifeSciences Friday? | 1 | Benzinga.com | ||
| 22.12.25 | Greenwich LifeSciences: Positive Studiendaten zu Brustkrebs-Immuntherapie treiben Aktie an | 1 | Investing.com Deutsch | ||
| 22.12.25 | Greenwich LifeSciences provides updates on Phase III breast cancer trial | 2 | Investing.com | ||
| 22.12.25 | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy | 794 | GlobeNewswire (Europe) | STAFFORD, Texas, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,... ► Artikel lesen | |
| 18.12.25 | Greenwich LifeSciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 15.12.25 | Why Is Greenwich LifeSciences Stock Surging After Data From Breast Cancer Vaccine? | 1 | Benzinga.com | ||
| 15.12.25 | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01 | 196 | GlobeNewswire (Europe) | STAFFORD, Texas, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,... ► Artikel lesen |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 93,10 | -0,21 % | Aufgrund von angeblichen Patentverletzungen zieht BioNTech gegen Moderna vor Gericht | Die Hersteller von Corona-Impfstoffen haben sich schon seit Jahren in den Haaren. Immer wieder gibt es Vorwürfe über Patentverletzungen. So auch in einem aktuellen Fall, bei dem BioNTech gegen den US-Hersteller... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,340 | -1,19 % | Viking Therapeutics: The High-Stakes Weight Loss Contender | ||
| KUROS BIOSCIENCES | 30,000 | +1,28 % | Kuros Biosciences AG: Kuros Biosciences to provide investor update at Octavian and Baader Bank Conferences | Kuros Biosciences to provide investor updateat Octavian and Baader Bank Conferences
Schlieren (Zürich), Switzerland, January 13, 2026 - Kuros Biosciences ("Kuros" or the "Company") a leader in innovative... ► Artikel lesen | |
| ABIVAX | 101,80 | -0,97 % | 2 Reasons Abivax Stock Could 10X by 2036 | ||
| CARDIFF ONCOLOGY | 1,650 | +0,73 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update | Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:• Robust ORR of 72.2% (vs 43.2% with combined SoC of... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 3,292 | +0,11 % | Iovance Biotherapeutics, Inc.: Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas | 50% Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE... ► Artikel lesen | |
| DENALI THERAPEUTICS | 17,705 | -0,28 % | Denali Therapeutics Inc.: Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights | Tividenofusp alfa (DNL310; ETV:IDS) launch readiness established ahead of April 5, 2026 Prescription Drug User Fee Act (PDUFA) target action date for Hunter syndromeDNL126 (ETV:SGSH) Phase 1/2 preliminary... ► Artikel lesen | |
| ARGENX | 651,00 | -0,34 % | BERNSTEIN RESEARCH stuft Argenx auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat die Einstufung für Argenx nach Zahlen zum vierten Quartal 2025 mit einem Kursziel von 875 Euro auf "Outperform" belassen. Fortschritte... ► Artikel lesen | |
| INSMED | 125,00 | -1,57 % | INSMED INC - Jetzt springt der Funke über! | ||
| CAPRICOR | 23,300 | -1,48 % | Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data | FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review processCompany expects to submit updates to the BLA in February 2026 to support continued FDA review SAN DIEGO,... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 7,500 | -1,32 % | Johnson Fistel, PLLP: Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses | San Diego, California--(Newsfile Corp. - February 19, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Zevra Therapeutics, Inc. (NASDAQ: ZVRA). The investigation... ► Artikel lesen | |
| REVOLUTION MEDICINES | 87,00 | +0,58 % | Revolution Medicines, Inc.: Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress | On track for readout of RASolute 302, a Phase 3 trial of daraxonrasib in second line metastatic PDAC, in first half of 2026Continues to advance broad late-stage pipeline, with five ongoing Phase 3... ► Artikel lesen | |
| SYNDAX PHARMACEUTICALS | 17,700 | -3,80 % | Syndax Pharmaceuticals, Inc.: Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | - Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 - - Revuforj- (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025 - - Niktimvo... ► Artikel lesen | |
| CORVUS PHARMACEUTICALS | 15,240 | -1,55 % | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M | SOUTH SAN FRANCISCO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the closing of an upsized underwritten... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,600 | +5,06 % | H.C. Wainwright cuts Summit Therapeutics stock price target on China trial timing uncertainty |
Das Unternehmen GREENWICH LIFESCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,440 (-1,56 %) liegt der Kurs bei 27,680 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GREENWICH LIFESCIENCES INC finden Sie auf Wallstreet Online.